Corcept Therapeutics Faces Class Action Lawsuit
Analysis based on 21 articles · First reported Feb 21, 2026 · Last updated Mar 22, 2026
The class action lawsuit against Corcept Therapeutics could negatively impact its stock price and investor confidence due to allegations of misleading statements and potential financial liabilities. This event highlights the importance of transparent communication from pharmaceutical companies regarding drug approval processes, potentially increasing scrutiny on similar firms.
A class action lawsuit has been filed against Corcept Therapeutics by Bronstein Gewirtz & Grossman LLC, alleging that Corcept Therapeutics and its officers made materially false and misleading statements regarding the clinical trials and regulatory prospects of its drug, relacorilant. The lawsuit claims that Corcept Therapeutics overstated the strength of its clinical trials and falsely conveyed confidence in relacorilant's regulatory prospects, despite the United States===Food and Drug Administration (FDA) repeatedly raising concerns about the adequacy of the clinical evidence. The lawsuit seeks to recover damages for investors who purchased Corcept Therapeutics securities between October 31, 2024, and December 30, 2025. Peretz Bronstein and Nathan Miller of Bronstein Gewirtz & Grossman LLC are involved in this case.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard